Navigation Links
Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
Date:12/28/2009

BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading provider of biopharmaceutical products in China, announced today that Weidong Yin, Chairman, President & CEO, was presented with the Annual Innovation Award by China Central Television (CCTV). As previously announced, Mr. Yin had been one of 18 nominees for the CCTV's China's 2009 Economic Man-of-the-Year. Results were announced on December 23, 2009 at an award ceremony held in Beijing.

Mr. Weidong Yin was honored because of his contribution to the battle against the H1N1 influenza pandemic; Sinovac vaccines protect human life and strengthen the Chinese people's confidence.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "I am very pleased to have received CCTV's 2009 Annual Innovation Award. As the first company worldwide to receive approval for the H1N1 vaccine, we have exemplified Sinovac's position as a true innovator in the global vaccine industry. We are proud that our entire portfolio of innovative vaccines continues to make a significant contribution to the health and well-being of Chinese citizens."

Recipients of the Top Ten 2009 Economic Man-of-the-Year award were CEO and president of Sina Charles Chao, China Minsheng Banking Corporation Chairman Dong Wenbiao, Shenzhen Capital Group Chairman Jin Haitao, chairman of Geely Automobile Holding Li Shufu, Guangdong Galanz Enterprise Group CEO Liang Chao-Hsien, chairman of Jiangsu Shagang Group Shen Wenrong, chairman and CEO at Neusoft Group Ltd Liu Jiren, Phoenix Publishing & Media Group chairman Tan Yue, Chongqing Changan Automobile Co., Ltd., chairman Xu Liuping, and chairman of New Oriental Education Group Yu Minhong. In addition, Liu Haitao, head of Shanghai Institute of Microsystem and Information Technology under the Chinese Academy of Sciences, received the Annual Innovation Award.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

     Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

     Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
5. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
6. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
7. Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009
8. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
9. Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
10. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
11. $10,000 ISSAC Award for Innovation Presented to MIT PhD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... May 26, 2016 Despite the volatility ... in this space. Today,s pre-market research on ActiveWallSt.com directs the ... Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ), and Five Prime Therapeutics Inc. (NASDAQ: FPRX ... at: http://www.activewallst.com/ On Wednesday, ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has been manufacturing ... laboratories all over the globe. Their cute firefly logo has been spreading to ... FireflySci makes spectrophotometer calibration standards that never require recalibration. These revolutionary standards ...
(Date:5/25/2016)... ... 2016 , ... The Ankle Plating System 3 and Small ... fractures of the distal tibia and fibula. This system marks Acumed's continued commitment ... is composed of seven plate families that span the lateral, medial, and posterior ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Scientists at the ... options being tried for mesothelioma may be hampering the research that could lead to ... Click here to read it now. , The team evaluated 98 ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):